201552-72-9

Basic information

• Product Name: 7-[[4-cyanophenyl]ethynyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione-4-propanoic acid ethyl ester
• Synonyms: 7-[[4-cyanophenyl]ethynyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione-4-propanoic acid ethyl ester
• CAS NO: 201552-72-9
• Molecular Weight: 401.422
• Mol File: 201552-72-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 7-[[4-cyanophenyl]ethynyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione-4-propanoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[[4-cyanophenyl]ethynyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione-4-propanoic acid ethyl ester(201552-72-9)
• EPA Substance Registry System: 7-[[4-cyanophenyl]ethynyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione-4-propanoic acid ethyl ester(201552-72-9)

Safety Data

• Hazardous Substances Data: 201552-72-9(Hazardous Substances Data)

Upstream product

• 167853-86-3 1-(diphenylmethyl)-4-(2-carboxyethyl)-7-iodo-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione ethyl ester 
• 220650-90-8 N-(2-diphenylmethylamino-5-iodobenzoyl)-β-alanine ethyl ester 
• 151978-67-5 3-(2-amino-5-iodo)benzamidopropionic acid ethyl ester 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 116027-10-2 5-iodoisatoic anhydride 
• 4244-84-2 ethyl β-alaninate hydrochloride 
• 3032-92-6 4-cyanophenylacetylene 
• 167853-84-1 4-(2-carboxyethyl)-7-iodo-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione ethyl ester 

Downstream Products

• 167854-08-2 8-[(4-cyanophenyl)ethynyl]-6-oxo-4H-[1,2,3,4]tetrazolo[4,5-a][1,4]benzodiazepine-5(6H)-propanoic acid ethyl ester 

Relevant articles and documents

Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists

Antagonists of the glycoprotein GPIIb/IIIa are a promising class of antithrombotic agents offering potential advantages over present antiplatelet agents (i.e., aspirin and ticlopidine). Novel tricyclic nonpeptidal GPIIb/IIIa antagonists have been prepared and evaluated in vitro as antagonists of fibrinogen binding to the purified GPIIb/IIIa receptor and as inhibitors of platelet aggregation. The work presented demonstrates the robustness of the benzodiazepinedione (BZDD) scaffold, which can be functionalized at the N1-C2 amide as well as at C7, to provide structural diversity and allow optimization of the physiochemical and pharmacological properties of the BZDD based GPIIb/IIIa antagonists. In addition, the resulting new class of tricyclic GPIIb/IIIa antagonists could be used to probe for additional binding interactions on the GPIIb/IIIa receptor and perhaps lead to BZDD based GPIIb/IIIa antagonists with increased potency. The tricyclic molecules reported herein demonstrate that a heterocyclic ring can be fused to the benzodiazepinedione scaffold with retention of anti-aggregatory potency and in the case of tetrazole 30i, increased potency relative to the bicyclic analogue 1c. Copyright (C) 1998 Elsevier Science Ltd.